Cargando…

RANKL/OPG in Breast Cancer — Extending Its Territory to BRCA Mutation Carriers

Detalles Bibliográficos
Autores principales:	Rachner, Tilman D., Rauner, Martina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2015
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4634749/ https://www.ncbi.nlm.nih.gov/pubmed/26629502 http://dx.doi.org/10.1016/j.ebiom.2015.09.035

Ejemplares similares

Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers
por: Widschwendter, Martin, et al.
Publicado: (2015)

Prospects of adjuvant RANKL inhibition in breast cancer?
por: Rachner, T D, et al.
Publicado: (2015)

Serum RANKL, osteoprotegerin (OPG), and RANKL/OPG ratio in nephrotic children
por: Wasilewska, Anna, et al.
Publicado: (2010)

Variation in breast cancer risk in BRCA1 and BRCA2 mutation carriers
por: Rebbeck, Timothy R, et al.
Publicado: (2008)

Plasma RANKL levels are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers
por: Zaman, Tasnim, et al.
Publicado: (2019)

From bone to breast and back - the bone cytokine RANKL and breast cancer
por: Hofbauer, Lorenz C, et al.
Publicado: (2011)

Discussion on the use of taxanes for treatment of breast cancers in BRCA1 mutations carriers
Publicado: (2007)

RANK/RANKL/OPG system in the intervertebral disc
por: Takegami, Norihiko, et al.
Publicado: (2017)

Serum levels of RANKL and OPG, and the RANKL/OPG ratio in bisphosphonate-related osteonecrosis of the jaw: Are they useful biomarkers for the advanced stages of osteonecrosis?
por: Bagan, Leticia, et al.
Publicado: (2017)

Targeting the RANKL/RANK/OPG Axis for Cancer Therapy
por: Ming, Jie, et al.
Publicado: (2020)

Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer
por: Kiechl, Stefan, et al.
Publicado: (2016)

Possible Prognostic Potential of RANKL and OPG in Metastatic Breast Cancer Egyptian Females
por: Shaker, Olfat Gamil, et al.
Publicado: (2020)

RAD52 S346X variant reduces breast cancer risk in BRCA2 mutation carriers
por: Biswas, Kajal, et al.
Publicado: (2020)

The Effect of RANKL/OPG Balance on Reducing Implant Complications
por: Kapasa, Elizabeth R., et al.
Publicado: (2017)

RANKL and OPG and their influence on breast volume changes during pregnancy in healthy women
por: Wunderle, Marius, et al.
Publicado: (2020)

An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA)
por: Chenevix-Trench, Georgia, et al.
Publicado: (2007)

Fatal attraction: why breast cancer cells home to bone
por: Hofbauer, Lorenz C, et al.
Publicado: (2008)

Breast cancer therapy for BRCA1 carriers: moving towards platinum standard?
por: Imyanitov, Evgeny N
Publicado: (2009)

Biology of the RANKL–RANK–OPG System in Immunity, Bone, and Beyond
por: Walsh, Matthew C., et al.
Publicado: (2014)

Dysregulation of the RANKL/RANK/OPG axis in thalassemia intermedia patients
por: Alfaqih, Mahmoud A., et al.
Publicado: (2018)

Influence of DNA methylation on the expression of OPG/RANKL in primary osteoporosis
por: Wang, Peng, et al.
Publicado: (2018)

Impact of periodontal treatment on the RANKL/OPG ratio in crevicular fluid
por: López Roldán, Andrés, et al.
Publicado: (2020)

RANKL/OPG ratio regulates odontoclastogenesis in damaged dental pulp
por: Nishida, Daisuke, et al.
Publicado: (2021)

The effect of vitamin D deficiency on the RANKL/OPG ratio in rats
por: Khalaf, Rawan M., et al.
Publicado: (2022)

Rank-Rankl-Opg Axis in Multiple Sclerosis: The Contribution of Placenta
por: Passaponti, Sofia, et al.
Publicado: (2022)

Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells
por: Göbel, Andy, et al.
Publicado: (2019)

RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives
por: Infante, Marco, et al.
Publicado: (2019)

Screening BRCA1 and BRCA2 Mutation Carriers for Breast Cancer
por: Warner, Ellen
Publicado: (2018)

Propofol attenuates osteoclastogenesis by lowering RANKL/OPG ratio in mouse osteoblasts
por: Lee, Do-Won, et al.
Publicado: (2018)

Assessment of Salivary Levels of RANKL and OPG in Aggressive versus Chronic Periodontitis
por: Teodorescu, Alexandra Cornelia, et al.
Publicado: (2019)

Association of RANKL and OPG Gene Polymorphism in Arab Women with and without Osteoporosis
por: Abdi, Saba, et al.
Publicado: (2021)

RANK/RANKL/OPG Signaling in the Brain: A Systematic Review of the Literature
por: Glasnović, Anton, et al.
Publicado: (2020)

Mechanical force regulates root resorption in rats through RANKL and OPG
por: Zhou, Jianli, et al.
Publicado: (2022)

Soy Isoflavones and Bone Health: Focus on the RANKL/RANK/OPG Pathway
por: Hooshiar, Saeedeh Hosseini, et al.
Publicado: (2022)

The RANK–RANKL–OPG System: A Multifaceted Regulator of Homeostasis, Immunity, and Cancer
por: De Leon-Oliva, Diego, et al.
Publicado: (2023)

Targeting syndecan-1 in breast cancer inhibits osteoclast functions through up-regulation of osteoprotegerin
por: Benad-Mehner, Peggy, et al.
Publicado: (2013)

Looking for BRCA1 and BRCA2 mutations in Asian women with breast cancer
por: Narod, Steven A.
Publicado: (2023)

Risks of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
por: Ahmed, M, et al.
Publicado: (2010)

Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
por: Metcalfe, K, et al.
Publicado: (2011)

Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
por: Kotsopoulos, Joanne, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_doatb411ubp3v93usj17jo5kgs